DiaMedica Announces Dr. Robert Stanton as Scientific Advisor for Upcoming Chronic Kidney Disease Trials
October 31 2017 - 11:24AM
DiaMedica Therapeutics Inc. (the
“
DiaMedica”) (TSX Venture:DMA)
(OTCQB:DMCAF) is pleased to announce that Dr. Robert Stanton, Chief
of the Kidney and Hypertension Section and a Principal Investigator
of Vascular Cell Biology at Joslin Diabetes Center, a Harvard
Medical School affiliate, will serve on DiaMedica’s Kidney
Scientific Advisory Board.
“Dr. Stanton has an extensive and successful
history of conducting research into the causes, complications, and
treatment options of kidney disease. In September of this year, he
published an important review paper titled “The Kallikrein-Kinin
System in Diabetic Kidney Disease1,” stated Mr. Rick Pauls,
President and CEO of DiaMedica. "Dr. Stanton will be an excellent
advisor for our upcoming clinical studies in patients with chronic
kidney disease."
Dr. Stanton commented, "I look forward to
assisting the advancement of therapies for treating patients with
chronic kidney disease.”
About Joslin Diabetes
Center
Joslin Diabetes Center, affiliated with Harvard
Medical School, is the world's preeminent diabetes research and
clinical care organization. Joslin, through its cutting-edge
research and innovative approaches to clinical care and education,
is dedicated both to helping people with diabetes live long,
healthy lives and to finding a cure.
About Dr.
Stanton
Robert C. Stanton, M.D. is the Chief of the Kidney
and Hypertension Section at Joslin Diabetes Center and is a
Principal Investigator in the Section on Vascular Cell
Biology. Dr. Stanton is an Associate Professor of
Medicine at Harvard Medical School where he is involved with
teaching at all levels. Dr. Stanton has lectured all
over the world. He has received three Honorary Professorships from
Universities in China. Dr. Stanton is an author of many
original articles and chapters.
About DiaMedica Therapeutics
Inc.
DiaMedica Therapeutics is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica's shares are listed
on the TSX Venture Exchange under the trading symbol "DMA" and on
the OTCQB under the trading symbol "DMCAF". For more information,
please visit www.diamedica.com. Follow us on social media –
Twitter, LinkedIn.
Contact:
Paul Papi Vice President of Business Development
DiaMedica Therapeutics Inc. Phone: (617) 899-5941
info@diamedica.com
Tweet this!
FORWARD-LOOKING
STATEMENTS
The statements made in this press release that
are not historical facts contain forward-looking information that
involves risk and uncertainties. All statements, other than
statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such
statements are based on management's exercise of business judgment
as well as assumptions made by and information currently available
to management. When used in this document, the words "may", "will",
"anticipate", "believe", "estimate", "expect", "intend" and words
of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view
of future events and are subject to certain risks and uncertainties
as contained in the DiaMedica's filings with the Canadian
securities regulators, all of which are available on SEDAR
(www.sedar.com). Should one or
more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking
statements. DiaMedica undertakes no obligation, and does not
intend, to update, revise, or otherwise publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of any unanticipated events, unless required by law. Although
management believes that expectations are based on reasonable
assumptions, no assurance can be given that these expectations will
materialize.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of the contents of this press release.
1Curr Opin Nephrol Hypertens 2017, 26:351–357.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024